نتائج البحث - D. Westerman
- يعرض 1 - 6 نتائج من 6
-
1
P361: EARLY MEASURABLE RESIDUAL DISEASE ANALYSIS IS ONLY PREDICTIVE OF SURVIVAL OUTCOMES AFTER TWO CYCLES OF TREATMENT IN ADULTS WITH B-LYMPHOBLASTIC LEUKEMIA RECEIVING HYPER-CVAD... حسب R. Nedumannil, D. Ritchie, A. Bajel, A. P. Ng, S. J. Harrison, D. Westerman
الحاوية / القاعدة HemaSphere (2022-06-01)احصل على النص الكامل
مقال -
2
P1306: CLINICAL AND GENOMIC ANALYSIS OF HIGH-GRADE TRANSFORMATION OF MARGINAL ZONE LYMPHOMA حسب C. Yannakou, D. Villa, C. Gould, Y. Kankanige, J. Lickiss, G. Ryland, S. Lade, G. Slack, W. Limvorapitak, C. Tam, J. Seymour, D. Westerman, P. Blombery
الحاوية / القاعدة HemaSphere (2022-06-01)احصل على النص الكامل
مقال -
3
B02 | SONROTOCLAX AND ZANUBRUTINIB AS FRONTLINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA DEMONSTRATES HIGH MINIMAL RESIDUAL DISEASE CLEARANCE RATES WITH GOOD TOLERABILITY: DATA F... حسب P. Ghia, J.D. Soumerai, C.Y. Cheah, M.A. Anderson, M. Lasica, E. Verner, S.S. Opat, S. Ma, R. Weinkove, R. Cordoba, S. Leitch, D. Westerman, S. Patel, Y. Fang, W. Ding, C.S. Tam
الحاوية / القاعدة Haematologica (2025-09-01)احصل على النص الكامل
مقال -
4
High ovarian hormones present during fear extinction reduce fear relapse through a nigrostriatal dopamine pathway حسب Alyssa A. Hohorst, Margaret K. Tanner, Rebecca Han, Kamryn M. Korth, Jessica D. Westerman, Carolina Sanchez Mendoza, Miles Q. Dryden, Lareina A. Alvarez, Remla A. Abdul, Esteban C. Loetz, Erik B. Oleson, Benjamin N. Greenwood
الحاوية / القاعدة Biology of Sex Differences (2025-06-01)احصل على النص الكامل
مقال -
5
C036 | SONROTOCLAX (SONRO; BGB-11417), A NOVEL BCL2 INHIBITOR, PLUS ZANUBRUTINIB DEMONSTRATES DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL: UPDATED PHASE-1 RESULTS حسب A. Tedeschi, C.Y. Cheah, C.S. Tam, M.A. anderson, E. Verner, M. Lasica, A. Arbelaez, S. Stilgenbauer, P. Browett, S. Leitch, E. González-Barca, M. Shadman, J-Z. Hou, H. Eradat, D. Westerman, Y. Fang, J. Hilger, S. Patel, S.S. Opat
الحاوية / القاعدة Haematologica (2025-09-01)احصل على النص الكامل
مقال -
6
P776: A PHASE 2, OPEN-LABEL, ASCENDING DOSE STUDY OF KER-050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES حسب S. Tan, A. Arbelaez, L. Chee, C. Y. Fong, D. Hiwase, G. Kannourakis, J. Kwan, J. Liang, A. Puliyayil, H. Rose, D. Ross, T.-C. Teh, D. Westerman, J. Wight, W. Feng, J. Lachey, A. McGinty, H. Natarajan, C. Rovaldi, S. Cooper
الحاوية / القاعدة HemaSphere (2022-06-01)احصل على النص الكامل
مقال
